Asker Healthcare Group AB: Interim Report 1 January-30 September 2025

Strong third quarter with earnings growth of 25 percent, of which 6 percent organic

1 July-30 September 2025

• Net sales amounted to SEK 4,129m (3,597), up 15 percent.
• Adjusted EBITA amounted to SEK 383m (306), up 25 percent, of which 6 percent was organic growth.
• The adjusted EBITA margin was 9.3 percent (8.5).
• EBIT amounted to SEK 242m (212), and profit for the quarter amounted to SEK 146m (81).
• Earnings per share before and after dilution amounted to SEK 0.37 (0.14).
• Return on net working capital (EBITA/NWC) amounted to 66.5 percent (66.3).
• Cash flow from operating activities amounted to SEK 439m (223).
• Asker signed four acquisition agreements during the quarter: Dartin (Czech Republic), Finmed Group (France), HNC (UK) and Oudshoorn (Netherlands).

1 January-30 September 2025

• Net sales amounted to SEK 12,111m (10,722), up 13 percent.
• Adjusted EBITA amounted to SEK 1,125m (956), up 18 percent, of which 6 percent was organic growth.
• The adjusted EBITA margin was 9.3 percent (8.9).
• EBIT amounted to SEK 728m (679) and profit for the period amounted to SEK 374m (268).
• Earnings per share before and after dilution amounted to SEK 0.91 (0.50).
• Return on net working capital (EBITA/NWC) amounted to 66.5 percent (66.3).
• Cash flow from operating activities amounted to SEK 760m (768).

CEO Johan Falk comments on the quarter

"Strong earnings growth of 25 percent, of which 6 percent organic, driven by our "twin engine". The organic business continues to grow at a healthy pace, and we have also welcomed additional high-quality companies, strengthening the Group and giving us a platform in France. We have never had such an exciting pipeline of new acquisition candidates."

For the full CEO comment, please see the interim report.

Presentation of the interim report

The interim report will be presented today, 6 November, at 10:00 CET by Asker's CEO Johan Falk and CFO Thomas Moss. You will find the webcast via this link. To participate via phone and ask questions, please register via this link.

For further information, please contact:

Thomas Moss, CFO and Head of Investor Relations
Phone: +46 70 219 79 05, E-mail: ir@asker.com

Emma Rheborg, Head of Communication
Phone: +46 73 313 62 17, E-mail: emma.rheborg@asker.com

Asker Healthcare Group is a partner to caregivers and patients across Europe providing medical products and solutions. We build and acquire leading companies that together support the healthcare system to improve patient outcomes, reduce total cost of care and ensure a fair and sustainable value chain. We are a European healthcare group that combines the entrepreneurial drive of strong local companies, with the abilities and collected knowledge of a large group - driving progress in the healthcare sector. The group has more than 4 500 employees in 19 countries and revenues amounting to SEK 16 billion.

The information was submitted for publication, through the agency of the contact person set out above, on 6 November 2025, at 8:10 a.m. CET.